Skip to content
Study details
Enrolling now

A Study of LY4515100 in Healthy Participants

Eli Lilly and Company
NCT IDNCT07339722ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

40

Study length

about 6 months

Ages

18–65

Locations

1 site in TX

About this study

This trial is testing the safety and how well LY4515100 is tolerated when given to healthy people. Blood tests will be done to see how the body processes the drug and its effects on the body. The study will last up to 30 days and include six overnight stays.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take LY4515100 via MAD
  • 2.Take LY4515100 via SAD
PhasePhase 1
Primary goalNumber of participants with one or more serious adverse event(s) (SAEs) of LY4515100

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low11%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Endpoints

Primary: Number of participants with one or more serious adverse event(s) (SAEs) of LY4515100

Secondary: PK: Maximum Observed Drug Concentration (Cmax) of LY4515100, PK: Time of maximum observed drug concentration (tmax) of LY4515100, Pharmacokinetics (PK): Area Under the Concentration versus Time Curve (AUC) of LY4515100